Overview

A 160-gene NGS panel aimed at solid lung tumors is a high-content profiling service intended for distributors, laboratories, and oncology channels that need broad genomic coverage from a single test. Before committing to a supplier, buyers should evaluate both the scientific content of the panel and the operational reliability of the service behind it. Sourcing the right assay is less about gene count alone and more about whether the genes, reporting, and logistics fit the clinical workflow you serve.

Gene Content and Its Fit for Lung Oncology

Lung tumors are biologically diverse, and guideline bodies such as NCCN recommend broad molecular profiling that looks beyond a single marker. A well-designed lung panel should at minimum address drivers that already have approved or clearly defined targeted options, including EGFR, ALK, ROS1, BRAF, MET exon 14, RET, KRAS, NTRK, and HER2, together with alterations that guide trial stratification. A 160-gene scope typically extends into additional tumor-suppressor and DNA-repair genes, giving clinicians a wider context for prognosis and clinical-trial matching. When sourcing, confirm the exact gene list and that each target is validated for the variant types it claims to report.

Operational Factors That Decide Usability

The strongest gene list is useless if the service cannot deliver reliably. Buyers should ask for the accepted specimen types, because most lung programs need FFPE tissue and plasma (cell-free DNA) compatibility when re-biopsy is not feasible. Clarify the typical turnaround, the accreditation or quality framework the lab operates under, and how ambiguous results are handled. Report format matters too: a structured, clinician-friendly summary with clear therapy mappings is far more adoptable than a raw variant dump.

Supply Stability and Commercial Terms

For distributors, continuity is a procurement issue, not just a scientific one. Evaluate minimum order quantities, kit stability and shelf life, cold-chain or ambient shipping requirements, and the supplier's track record for consistent reagent supply. A panel that requires complex local instrumentation may suit a central lab but not a point-of-care reseller, so match the format to your channel before signing.

FAQ

Q: Is a bigger gene list always better for lung cancer? A: Not necessarily. Coverage is only valuable if the added genes are validated and clinically interpretable; an unvalidated long list can create uncertainty without improving decisions.

Q: Should I require plasma testing support when sourcing? A: For lung oncology, plasma-compatible testing is increasingly expected because tissue is often scarce, so it is a strong differentiator to verify.

Q: How do I compare two panels with similar gene counts? A: Compare the validated gene list, specimen flexibility, turnaround, report quality, and the supplier's quality certifications rather than the headline number alone.